We are a newly organized blank check company incorporated on April 1, 2026, as a
Cayman Islands exempted company incorporated for the purpose of effecting a
merger, share exchange, asset acquisition, share purchase, reorganization or
similar business combination with one or more businesses, which we refer to
throughout this prospectus as our initial business combination. To date, our
efforts have been limited to organizational activities as well as activities
related to this offering.
While we may pursue an acquisition opportunity in any business, industry, sector
or geographical location, we intend to focus on industries that complement our
management teamβs background, and to capitalize on the ability of our management
team to identify and acquire a business, focusing on the healthcare or
healthcare-related industries. In particular, we are targeting companies in the
drug development and commercialization, diagnostic and healthcare technology and
service sectors where our management has extensive investment experience.
We may pursue a transaction with a target that is affiliated with RA Capital
Management, our sponsor, directors or members of our management team. We may
pursue a transaction in which our shareholders immediately prior to the
completion of our initial business combination would collectively own a minority
interest in the post-business combination company.
---
Our sponsor is an affiliate of RA Capital Management, a leading life sciences
focused investment firm with over $15 billion of regulatory assets under
management as of December 31, 2025. Since its launch in 2002, RA Capital
Management has focused primarily on the healthcare industry. Matthew Hammond,
PhD, our founding Chief Executive Officer and Director is a Partner on the
investment team at RA Capital Management and Henry Stusnick, our founding Chief
Business Officer and Operating Officer, is an Analyst on the investment team at
RA Capital Management.
---
Our executive offices are located at 600 Fifth Avenue, 23rd Floor, New York, NY
10020. Our telephone number is +1 (617) 778 2500.
